1380
b i o c h e m i c a l p h a r m a c o l o g y 7 5 ( 2 0 0 8 ) 1 3 7 0 – 1 3 8 0
[10] Warrilow D, Gardner J, Darnell GA, Suhrbier A, Harrich D.
HIV type 1 inhibition by protein kinase C modulatory
compounds. AIDS Res Hum Retroviruses 2006;22:854–64.
[11] Hamer DH, Bocklandt S, McHugh L, Chun TW, Blumberg
PM, Sigano DM, et al. Rational design of drugs that induce
human immunodeficiency virus replication. J Virol
2003;77:10227–36.
[12] Bocklandt S, Blumberg PM, Hamer DH. Activation of latent
HIV-1 expression by the potent anti-tumor promoter 12-
deoxyphorbol 13-phenylacetate. Antivir Res 2003;59:89–98.
[13] Zayed S, Hafez A, Adolf W, Hecker E. New tigliane and
daphnane derivatives from Pimelea prostrata and Pimelea
simplex. Experientia 1977;33:1554–5.
[14] Gustafson KR, Cardellina II JH, McMahon JB, Gulakowski RJ,
Ishitoya J, et al. A nonpromoting phorbol from the samoan
medicinal plant Homalanthus nutans inhibits cell killing by
HIV-1. J Med Chem 1992;35:1978–86.
[15] Trushin SA, Bren GD, Asin S, Pennington KN, Paya CV,
Badley AD. Human immunodeficiency virus reactivation by
phorbol esters or T-cell receptor ligation requires both
PKCalpha and PKCtheta. J Virol 2005;79:9821–30.
[16] Hezareh M, Moukil MA, Szanto I, Pondarzewski M, Mouche
S, Cherix N, et al. Mechanisms of HIV receptor and co-
receptor down-regulation by prostratin: role of
[25] Hathcock KS. In vitro assays for mouse B and T cell
function. Isolation and fractionation of lymphocytes. In:
Coligan JS, Kruisbeek AM, Margulies DH, Shevach EM,
Strober W, editors. Current protocols in immunology.
Greene Publishing Associates and Wiley-Interscience; 1991.
p. 3.2.1–3.
[26] Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D,
Verdin E, et al. Prostratin antagonizes HIV latency by
activating NF-kappaB. J Biol Chem 2004;279:42008–17.
[27] Karin M, Ben-Neriah Y. Phosphorylation meets
ubiquitination: the control of NF-[kappa]B activity. Annu
Rev Immunol 2000;18:621–63.
[28] Yang X, Chen Y, Gabuzda D. ERK MAP kinase links cytokine
signals to activation of latent HIV-1 infection by
stimulating a cooperative interaction of AP-1 and NF-
kappaB. J Biol Chem 1999;274:27981–8.
[29] Tuthill MC, Oki CE, Lorenzo PS. Differential effects of
bryostatin 1 and 12-O-tetradecanoylphorbol-13-acetate on
the regulation and activation of RasGRP1 in mouse
epidermal keratinocytes. Mol Cancer Ther 2006;5:602–10.
[30] Mochly-Rosen D, Henrich CJ, Cheever L, Khaner H, Simpson
PC. A protein kinase C isozyme is translocated to cytoskeletal
elements on activation. Cell Regul 1990;1:693–706.
[31] Wang QJ, Bhattacharyya D, Garfield S, Nacro K, Marquez VE,
Blumberg PM. Differential localization of protein kinase C
delta by phorbol esters and related compounds using a
fusion protein with green fluorescent protein. J Biol Chem
1999;274:37233–9.
conventional and novel PKC isoforms. Antivir Chem
Chemother 2004;15:207–22.
[17] Newton AC. Protein kinase C: structural and spatial
regulation by phosphorylation, cofactors, and
macromolecular interactions. Chem Rev 2001;101:2353–64.
[18] Hall C, Lim L, Leung T. C1, see them all. Trends Biochem Sci
2005; 30:169–71.
[32] Steinberg SF. Distinctive activation mechanisms and
functions for protein kinase Cdelta. Biochem J
2004;384:449–59.
[19] Slater SJ, Ho C, Kelly MB, Larkin JD, Taddeo FJ, Yeager MD,
et al. Protein kinase Calpha contains two activator binding
sites that bind phorbol esters and diacylglycerols with
opposite affinities. J Biol Chem 1996;271:4627–31.
[20] Zhang G, Kazanietz MG, Blumberg PM, Hurley JH. Crystal
structure of the cys2 activator-binding domain of protein
kinase C delta in complex with phorbol ester. Cell
1995;81:917–24.
[21] Wang QJ, Fang TW, Fenick D, Garfield S, Bienfait B, Marquez
VE, et al. The lipophilicity of phorbol esters as a critical
factor in determining the pattern of translocation of
protein kinase C delta fused to green fluorescent protein. J
Biol Chem 2000;275:12136–4.
[22] Sakai N, Sasaki K, Ikegaki N, Shirai Y, Ono Y, Saito N. Direct
visualization of the translocation of the gamma-subspecies
of protein kinase C in living cells using fusion proteins with
green fluorescent protein. J Cell Biol 1997;139:1465–76.
[23] Jordan A, Defechereux P, Verdin E. The site of HIV-1
integration in the human genome determines basal
transcriptional activity and response to Tat transactivation.
EMBO J 2001;20:1726–38.
[33] Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P,
Parker PJ. Protein kinase C isotypes controlled by
phosphoinositide 3-kinase through the protein kinase
PDK1. Science 1998;281:2042–5.
[34] Vandergeeten C, Quivy V, Moutschen M, Van Lint C, Piette J,
Legrand-Poels S. HIV-1 protease inhibitors do not interfere
with provirus transcription and host cell apoptosis induced
by combined treatment TNF-alpha + TSA. Biochem
Pharmacol 2007;73:1738–48.
[35] Hezareh M. Prostratin as a new therapeutic agent targeting
HIV viral reservoirs. Drug News Perspect 2005;18:496–500.
[36] Hecker E. Cell membrane associated protein kinase C as
receptor of diterpene ester co-carcinogens of the tumor
promoter type and the phenotypic expression of tumors.
Arznezimittel-Forsch 1985;35:1890–903.
[37] Mor A, Philips MR. Compartmentalized Ras/MAPK
signaling. Annu Rev Immunol 2006;24:771–800.
[38] Roose JP, Mollenauer M, Gupta VA, Stone J, Weiss A. A
diacylglycerol-protein kinase C-RasGRP1 pathway directs
Ras activation upon antigen receptor stimulation of T cells.
Mol Cell Biol 2005;25:4426–41.
[24] Sancho R, Calzado MA, Di Marzo V, Appendino G, Munoz E.
Anandamide inhibits nuclear factor-kappaB activation
through a cannabinoid receptor-independent pathway. Mol
Pharmacol 2003;63:429–38.
[39] Zheng Y, Liu H, Coughlin J, Zheng J, Li L, Stone JC.
Phosphorylation of RasGRP3 on threonine 133 provides a
mechanistic link between PKC and Ras signaling systems in
B cells. Blood 2005;105:3648–54.